Source comparison
MOTS-c vs GLP-1 Agonists vs Traditional Fat Loss Compounds: Mechanism Comparison
MOTS-c (Mitochondrial Peptide) AMPK activation → inhibits ACC, upregulates CPT1 Directly improves insulin sensitivity in muscle and adipose tissue Enhances mitochondrial beta-oxidation of fatty acids No direct appetite suppression Best suited for metabolic dys
This comparison does not assign a generated winner or score.
- MOTS-c (Mitochondrial Peptide)
- AMPK activation → inhibits ACC, upregulates CPT1
- Directly improves insulin sensitivity in muscle and adipose tissue
- Enhances mitochondrial beta-oxidation of fatty acids
- No direct appetite suppression
- Best suited for metabolic dysfunction cases where insulin resistance blocks fat loss despite deficit
- GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)
- Slows gastric emptying, extends satiety hormone elevation
- Indirect improvement via weight loss and reduced hepatic glucose output
- Modest. Primarily driven by caloric deficit from appetite suppression
- Strong central appetite suppression
- Superior for patients who struggle with hunger and portion control; less effective if insulin resistance remains unaddressed
- Beta-Adrenergic Agonists (Clenbuterol, Albuterol)
- Sympathetic nervous system stimulation, increases cAMP
- No direct effect on insulin signaling
- Lipolysis via hormone-sensitive lipase activation
- Mild appetite suppression from CNS stimulation
- Effective for short-term fat mobilization but carries cardiovascular risk; does not address underlying metabolic dysfunction
- AMPK Activators (Metformin, Berberine)
- AMPK activation via energy stress signaling
- Improves hepatic and peripheral insulin sensitivity
- Increases fat oxidation in liver and muscle
- Minimal to none
- Metformin shows 5–7% body weight reduction in diabetic populations; berberine less studied but similar mechanism profile